PMC:7696151 / 84214-84397
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2531 | 123-131 | Species | denotes | patients | Tax:9606 |
| 2541 | 30-33 | Chemical | denotes | HCQ | MESH:D006886 |
| 2542 | 147-159 | Chemical | denotes | temozolomide | MESH:D000077204 |
| 2559 | 110-122 | Disease | denotes | glioblastoma | MESH:D005909 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T205 | 110-122 | Phenotype | denotes | glioblastoma | http://purl.obolibrary.org/obo/HP_0012174 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T537 | 0-183 | Sentence | denotes | The anticancer effect of free HCQ at 200–800 mg/day p.o. has been evaluated in two similar clinical trials on glioblastoma patients in concomitant temozolomide drugs and radiotherapy. |